| Year |
Citation |
Score |
| 2022 |
Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, ... ... Malhotra SV, et al. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports. Medicine. 3: 100502. PMID 35243415 DOI: 10.1016/j.xcrm.2021.100502 |
0.315 |
|
| 2021 |
Eldhose B, Pandrala M, Xavier C, Mohamed AA, Srivastava S, Sunkara AD, Dobi A, Malhotra SV. New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. Acs Medicinal Chemistry Letters. 12: 1703-1709. PMID 34790292 DOI: 10.1021/acsmedchemlett.1c00308 |
0.331 |
|
| 2021 |
Singh R, Kumar R, Pandrala M, Kaur P, Gupta S, Tailor D, Malhotra SV, Salunke DB. Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation. Archiv Der Pharmazie. e2000393. PMID 33749032 DOI: 10.1002/ardp.202000393 |
0.301 |
|
| 2019 |
Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Frontiers in Oncology. 9: 801. PMID 31555580 DOI: 10.3389/Fonc.2019.00801 |
0.324 |
|
| 2019 |
Tailor D, Resendez A, Kumar V, Going C, Pitteri S, Malhotra S. Abstract 5275: Cancer specific caloric restriction using novel small molecule improves the therapeutic regime for triple negative breast cancer Cancer Research. 79: 5275-5275. DOI: 10.1158/1538-7445.Am2019-5275 |
0.35 |
|
| 2018 |
Going CC, Tailor D, Kumar V, Birk AM, Pandrala M, Rice MA, Stoyanova T, Malhotra S, Pitteri SJ. Quantitative proteomic profiling reveals key pathways in the anti-cancer action of methoxychalcone derivatives in triple negative breast cancer. Journal of Proteome Research. PMID 30200768 DOI: 10.1021/Acs.Jproteome.8B00636 |
0.33 |
|
| 2018 |
Mohamed AA, Xavier CP, Sukumar G, Tan SH, Ravindranath L, Seraj N, Kumar V, Sreenath TL, McLeod DG, Petrovics G, Rosner I, Srivastava M, Strovel J, Malhotra SV, LaRonde NA, et al. Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth. Cancer Research. PMID 29712692 DOI: 10.1158/0008-5472.Can-17-2949 |
0.36 |
|
| 2017 |
Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. 1,4-Substituted Triazoles as Non-Steroidal Antiandrogens for Prostate Cancer Treatment. Journal of Medicinal Chemistry. PMID 28272894 DOI: 10.1021/acs.jmedchem.7b00105 |
0.346 |
|
| 2017 |
Mohamed AA, Xavier CP, Sukumar G, Banister SD, Kumar V, Tan S, Katta S, Ravindranath L, Jamal M, Sreenath T, McLeod DG, Petrovics G, Dobi A, Srivastava M, Malhotra S, et al. Abstract 1183: Structure-activity studies and biological evaluations of ERGi-USU, a highly selective inhibitor for ERG-positive prostate cancer cells Cancer Research. 77: 1183-1183. DOI: 10.1158/1538-7445.Am2017-1183 |
0.382 |
|
| 2017 |
Mohamed A, Xavier C, Sukumar G, Banister S, Kumar V, Tan S, Katta S, Ravindranath L, Jamal M, Sreenath T, McLeod D, Petrovics G, Dobi A, Srivastava M, Malhotra S, et al. MP87-14 STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF ERGI-USU, A HIGHLY SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2718 |
0.376 |
|
| Show low-probability matches. |